• Comprehensive menu in inflammatory diseases and oncology
  • Validated on principle drug and biosimilars
  • Ready to use reagents
  • Standardised protocols from sample collection to result interpretation
  • Automation ready – validated on several open platform ELISA systems

LISA-TRACKER Duo Vedolizumab is an enzyme linked immunoassay for the quantitative determination of Vedolizumab (anti-α4β7 integrin) and anti-Vedolizumab antibodies in human serum samples.

Vedolizumab is a humanised monoclonal antibody against α4β7 integrin. It is recommended for the treatment of Inflammatory bowel disease, especially ulcerative colitis and Crohn’s disease. It binds to α4β7 integrin, responsible of the immune cells (lymphocytes) attraction in the digestive tract and limits the intestinal inflammation which appears during these pathologies.  During the treatment, some patients can develop antibodies against Vedolizumab.

  • Cherry LN et al. Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn’s disease. Therapeutic Advances in Chronic Disease, Vol.6(5), 224-233, 2015.
  • Feagan BG et al. Induction and Maintenance Therapy with Vedolizumab, a novel biologic therapy for ulcerative colitis.  Gastroenterology & Hepatology, 10, Issue 1, 2014.
  • Feagan BG et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis.  The new England journal of medicine, 369, 699-710, 2013.
  • McLean LP et al. Vedolizumab for the treatment of ulcerative colitis and Crohn’s disease.  Immunotherapy, 4, 883-898, 2012.
  • Petrovic A et al. LPAM (α4β7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease.  Blood, 103, 4, 2004.
  • Rosario M et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease.  Alimentary Pharmacology and Therapeutics, 2015.
  • Sandborn WJ et al. Vedolizumab as induction and maintenance therapy for crohn’s disease.  The new England journal of medicine, 369, 711-721, 2013.
  • Soler D et al. The binding specificity and selective antagonism of vedolizumab, an anti- α4β7integrin therapeutic antibody in development for inflammatory bowel diseases.  The journal of pharmacology and experimental therapeutics, 330, 864-875, 2009.
  • Yu Jin et al. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis.  World Journal of Gastroenterology, 21, issue 20, 2015.

LISA-TRACKER Vedolizumab

LISA-TRACKER anti-Vedolizumab

ImmunoTROL LISA-TRACKER Vedolizumab

ImmunoTROL LISA-TRACKER anti-Vedolizumab